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INTRODUCTION 
  
 Liver disease are most common all over the world   
(prevalence being 4-17.5percent) as well as in India and the 
prevalence of liver disease likely to be increased in future (1). 
Among the various functions of liver, one function is 
synthesis of carrier proteins and metabolism of hormones. 
Thus liver diseases, have been shown to be associated with 
various endocrinal disturbances(2,3). The liver dysfunction 
leads to secondary dysfunction of endocrine glands directly 
due to the toxic effects and indirectly by the alteration of the 
carrier protein synthesis. Therefore ,chronic liver disease may 
be accompanied by signs of apparent hormonal imbalance. 
 Thyroxine and Tri-iodothyronine are essential for normal 
organ growth, development and function. These hormones 
regulate the basal metabolic rate of all cells, including 
hepatocytes, and thereby modulate hepatic function. Liver 
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plays an important role in the metabolism of thyroid hormone 
like conjugation, peripheral deiodination and synthesis of 
thyroid binding globulin(4-7.)Hence ,it is not surprising that 
thyroid dysfunction have been reported in various spectra of 
liver disease and associated with severity of liver disease(8-10). 
“NORMAL THYROID FUNCTION IS DEPENDENT ON A 
NORMALLY FUNCTIONING THYROID AND LIVER 
AXIS” 
 In normal subjects, thyroid gland secretes 110nmol of 
thyroxine and 10nmol of tri- iodothyronine each day. Even 
though Thyroxine is secreted at a higher rate quantitatively , it 
is regarded as a pro hormone that requires de-iodination and 
conversion to T3 to become biologically active. 
Iodo-thyroxineselenodeiodinase 
Enzyme system (D1, D2) 
T4----------------------------------------------------T3 
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 This reaction occurs in thyroid and extrathyroidal 
system. Extrathyroidal includes Liver, kidney   and Pitutary. 
Out of this about 30-40 percent of extrathyroidal conversion 
occurs in Liver.  
 Inspite of this, LIVER also plays an important role in 
inactivation of thyroid hormones by D3. In addition to central 
role in de iodination to active and deactive thyroid hormones, 
the liver performs specific functions relating to thyroid 
hormone transport. >99% of thyroid hormones bound to 
thyroxine binding globulin, thyroid binding prealbumin and 
albumin in plasma. The free hormone component is in 
equilibrium with protein bound component and this free form 
is available for metabolic function. 
 Various  studies indicated that during various phase of 
liver disease the serum T4 concentrationaltered accordingly 
and related also to the disease progression. T3 can be used as 
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good laboratory index in evaluating the status of liver disease. 
The serum T3 concentration and those liver factors, such as 
bilirubin are now can be regarded as valuable index in the 
following the trends in thyroid-liver patho physiology. It is 
vital to measure the free and T4 thyroid Stimulating Hormone 
(TSH) and any other laboratory test which may be in any help 
to avoid misdiagnosis of a hypothyroid patients suffering from 
liver diseases. Few endocrinedisorders associated with CLD 
are even reported to reverse after liver transplantation(6).The 
low total and FT3 levels may be regarded as an adaptive 
hypothyroid state that serves to reduce the basal BMR within 
hepatocytes and preserve liver function and total body protein 
stores(5).It has been suggested that this adaptation may confer 
a survival advantage, which adapts an organism to chronic 
illness by reducing the basal metabolic rate within cells and 
thereby reducing caloric requirements. 
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 Hence the present study is to establishing the concrete 
relationship between hypothyroidism (by measuring FT3, 
FT4, TSH) and chronic liver disease and consider FT3 as the 
factor of severity by correlating with child-pugh score by 
using clinical and biochemical parameters available in our 
hospital. 
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REVIEW OF LITERATURE 
 
 Chronic liver disease in the clinical context is a disease 
process of the liver that exceeds more than 6 months, that 
involves a process of progressive destruction and regeneration 
of the liver parenchyma that leading to fibrosis and 
cirrhosis(11). Patients with a history of chronic liver disease 
with gastroesophageal varices, ascites, or hepatic 
encephalopathy are likely to have cirrhosis, and liver biopsy is 
not essential in such cases for confirming cirrhosis. In patients 
with a diagnosis of chronic liver disease without these 
complications, physical findings of an enlarged left hepatic 
lobe with splenomegaly, along with the cutaneous stigmata of 
liver disease suggestive of cirrhosis, especially in the setting 
of thrombocytopenia and impaired hepatic synthetic function 
(e.g., hypoalbuminemia, prolongation of the prothrombin 
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time). If physical and laboratory findings are not suggestive of 
cirrhosis, imaging studies can help make a diagnosis of 
cirrhosis. A small nodular liver with splenomegaly and intra-
abdominal collaterals and the presence of ascites on 
abdominal US (or other cross-sectional imaging study) 
suggests cirrhosis(12).This process distorts the normal liver 
architecture, interferes with blood flow through the liver and 
disrupts the functions of liver. 
Classification of cirrhosis: 
1.MORPHOLOGICAL CLASSIFICATION: 
Cirrhosis was historically classified morphologically as 
micronodular, macronodular and mixed. 
Micronodular cirrhosis, characterized by nodules less than 
3mm in diameter, was believed to be caused by alcohol, 
hemochromatosis, cholestatic causes of cirrhosis and hepatic 
venous outflow obstruction. 
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Macronodular cirrhosis, characterized by various sized 
nodules more than 3mm in diameter was believed to be 
secondary to chronic viral hepatitis. 
 Although important from a historical perspective, the 
morphological classification system has number of limitations 
and has thus largely been abandoned. First, it is relatively non 
specific with regard to etiology. Second, the morphological 
appearance of the liver may change as the liver disease 
progresses; micronodular cirrhosis usually progresses to 
macronodular cirrhosis. 
 Third, serological markers available today are more 
specific than morphological appearance of the liver for 
determining the etiology of cirrhosis. 
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2.ETIOLOGICAL CLASSIFICATION OF CIRRHOSIS 
 Classification of cirrhosis according to etiology as this 
approach may help to determine prophylactic and therapeutic 
measures as well as prognosis. If all diagnostic options are 
employed and the patient cooperates optimally. An etiological 
identification of cirrhosis is possible in almost all cases today. 
Due to improved detailed diagnostic options, the group of so 
called cryptogenic cirrhosis has been consistently 
reduced(<10% of cases). 
HEPATITIS AND OTHER VIRUSES:(post hepatitis) 
 Worldwide, hepatitis B is the most common cause of 
cirrhosis, but in Egypt and United states hepatitis C is the 
most common cause. 
 Three viruses are responsible for post-hepatic cirrhosis, 
HBV,HCV and HDV. The latter is a defective organism 
which can replicate when co-infection with HBV is present. 
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Chronicinfection with these viruses account for the majority 
of the cases of chronic active hepatitis which give rise to post-
hepatic cirrhosis. 
AUTOIMMUNE HEPATITIS: 
 In autoimmune hepatitis the body’s immune system 
attacks the liver causing cell damage that leads to cirrhosis. 
TOXIC AND DRUG INDUCED 
 Alcoholic liver disease, it encompasses the hepatic 
manifestations of alcohol over consumption, including fatty 
liver, alcoholic hepatitis, chronic hepatitis with hepatic 
fibrosis or cirrhosis. Although steatosis(fatty liver) will 
develop in any individual who consumes large quantity of 
alcohol beverages over a long period of time, this process is 
transient a reversible. Of all chronic heavy drinkers, only 15-
20% develop cirrhosis or hepatitis, which can occur 
concomitantly or in succession. Chronic consumption of 
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alcohol results in the secretion of pro inflammatory cytokine 
(TNF-alpha, Interleukin 6 and Interleukin 8) and oxidative 
stress. These factors cause inflammation, apoptosis and 
eventually fibrosis of liver cells. 
 Drugs like amiodarone, methotrexate, nitrofurantoin may 
lead to cirrhosis. 
METABOLIC 
 Non-alcoholic fatty liver disease – NAFLD is a condition 
defined by excessive fat accumulation in the form of 
triglycerides (steatosis) in the liver. A subgroup of 
NAFLD patients displays liver cell injury and 
inflammation in addition to excessive fat(steatohepatitis). 
The latter condition, designated NASH, is virtually 
indistinguishable histologically from alcoholic 
steatohepatitis. 
 
20 
 Hemochromatosis. 
 Wilson’s disease. 
COMPLICATIONS 
1. Variceal bleeding- Variceal bleeding is caused by portal 
hypertension, which is an increase in the pressure within 
the portal vein ( the large vessel that carries blood from 
the digestive organs to the liver). This increase in 
pressure is caused by a blockage of blood flow through 
the liver as a result of cirrhosis. Increased pressure in the 
portal vein causes other veins in the body to enlarge 
(varices), such as those in the esophagus and stomach, it 
bypass the blockage. These varices become fragile and 
can bleed easily, causing severe hemorrhagic and fluid in 
the abdomen. 
2. Hepatic encephalopathy: hepatic encephalopathy most 
often occurs when cirrhosis has been present for a long 
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time. Toxins produced in our intestines are normally 
detoxified by the liver, but once cirrhosis occurs, the 
liver cannot detoxify as well. Toxins get in to the 
bloodstream and can cause confusion, changes in 
behavior and even coma. 
3. Ascites: It is the accumulation of the fluid in the 
peritoneal cavity due to increase in intrahepatic 
resistance, increased portal pressure, vasodilation of 
splancnic arterial system and hypoalbuminemia. 
4. Synthetic dysfunction: 
a.Hypoalbuminemia 
 b.Coagulopathy 
5. Hepatopulmonary syndrome: Liver cirrhosis can lead to 
hepatopulmonary syndrome characterized by platypnea 
and orthodeoxia. 
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6. Hepatorenal syndrome-Functional renal failure within 
renal pathology occurring in about 10%of patients with 
advanced cirrhosis due to increased in renal vascular 
resistance accompanied by a reduction in systemic 
vascular resistance. 
7. Hepatocellular carcinoma. 
Child pugh scoring- 
 It was originally used to predict mortality during surgery, 
it is now used to determine the prognosis, as well as the 
required strength of treatment and the necessity of liver 
transplantation. 
  The score employs five clinical measures of liver 
disease. Each measure is scored 1-3, with 3 indicates most 
severe derangement. 
 
23 
 
     MEASURE 1 POINT       2 POINTS      3 POINTS 
Total 
bilrubin,µmol/l(mg/dl) 
<34(<2) 34-50(2-3) >50(>3) 
Serum albumin, g/dl >3.5 2.8-3.5 <2.8 
PT INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to severe 
Hepatic encephalopathy None Grade 1-2 Grade 3-4 
 
 Chronic liver disease is classified into Child-pugh class 
A to C, employing the added score from above  
POINTS CLASS ONE YEAR 
SURVIVAL 
TWO YEAR 
SURVIVAL 
      5-6         A              100%                85% 
      7-9         B               81%                57% 
    10-15        C                45%                35% 
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Physiology of the hypothalamic-pitutary-thyroid axis: a 
short review 
 The thyroid gland participates with the hypothalamus 
and pituitary in a classic feedback control loop. There is a 
close relationship among the hypothalamus, the anterior 
pituitary, the thyroid gland and still higher centers in the 
brain, the function of the entire complex being modi ed in a 
typical negative-feedback manner by the availability of the 
thyroid hormones. The parvocellular region of the 
paraventricular nuclei of the hypothalamusis the source of the 
TRH that regulates TSH secretion. TRH travels in the axons 
of the peptidergic neurons through the median eminence and 
is released close to the hypothalamic-pituitary portal plexus.  
 Thyrotropin (TSH) is the major regulator of the 
morphologic and functional states of the thyroid. TRH 
increases and thyroid hormone suppresses, and these are the 
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two most important infuences on TSH synthesis. In normal 
serum, TSH is present at concentrations between 0.5 and 5.0 
mU/L. The level is increased in primary hypothyroidism and 
reduced in thyrotoxicosis. The plasma TSH half-life is about 3 
minutes, and production rates in humans are 40 to 150 
mU/day. Circulating TSH displaysboth pulsatile and circadian 
variations. The former are characterized by  uctuations at 1- 
to 2-hour intervals. The magnitude of TSH pulsations is 
decreased during fasting orillness and after surgery.  The 
circadian variation is characterized by a nocturnal surge that 
precedes the onset of sleep and appears to be independent of 
the cortisol rhythm and of fluctuations in serum T4 and T3 
concentrations(13).There is a linear inverse relationship 
between the serum free T4 concentration and the log of the 
TSH, making the serum TSH concentration an exquisitely 
sensitive indicator of the thyroid state of patients with an 
intact hypothalamic-pituitary axis. 
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 Measurement of serum TSH is the primary screening test 
for thyroid function. TSH levels vary diurnally by up to 
approximately 50% of mean values(14).TSH secretion is very 
sensitive to both minor increase and decrease in serum FT4, 
and abnormal TSH levels occur during developing 
hypothyroidism and hyperthyroidism before FT4 
abnormalities are detectable(15). 
 Somatostatin (somatotropin release-inhibiting factor 
[SRIF]), acting through inhibitory G protein (Gi), decreases 
TSH secretion in vitro and in vivo, but prolonged treatment 
with a somatostatin analogue does not cause 
hypothyroidism(16,17). Similar acute effects occur during 
dopamine infusion and the administration of bromocriptine, a 
dopamine agonist; both of these agents inhibit 
adenylatecyclase. Conversely, blockade of the dopamine 
receptor by metoclopramide increases the basal serum TSH 
concentration in both euthyroid and hypothyroid patients. 
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These findings indicate that dopamine is a regulator of TSH 
secretion, but chronic administration of dopamine agonists 
(e.g., for the treatment of prolactinoma) does not cause central 
hypothyroidism, indicating that compensatory mechanisms 
negate these acute effects(18). 
 Neurotransmitters are important direct and indirect 
modulators in TSH synthesis and secretion. A complex 
network of neurotransmitter neurons terminates on the cell 
bodies of hypophysiotropic neurons, and several 
neurotransmitters (e.g., dopamine) are directly released into 
hypophyseal portal blood, exerting direct effects on anterior 
pituitary cells. Furthermore, many dopaminergic, 
serotoninergic, histaminergic, catecholaminergic, opioidergic, 
and GABAergic systems project from hypothalamic orother 
brain regions to the hypophysiotropic neurons involved in 
TSH regulation. 
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IODINE AND THE SYNTHESIS AND SECRETION OF 
THYROID HORMONES 
  The function of the thyroid gland is to generate the 
quantity of thyroid hormone necessary to meet the demands of 
the peripheral tissues. This requires iodide uptake by the 
thyroidal sodium-iodide symporter (NIS), its transfer to the 
colloid, and its oxidation by thyroid peroxidase (TPO). 
 TPO also catalyzes the coupling of two molecules of DIT 
or one ofDIT and one of MIT, leading to formation of T4 and 
T3, respectively (see late discussion). These products are then 
stored within the colloid, still as part of the Tg molecule. 
Pinocytosis of stored colloid leads to the formation of 
phagolysosomes,the colloid droplets in which Tg is digested 
by speci c proteases to release T4, T3, DIT, and MIT as the 
droplet is translocated toward the basal portion of the cell. T4 
and T3 are transported out of the phagolysosomes and across 
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the basolateral cell membrane, exit the cell, and enter 
circulation; DIT and MIT are deiodinated by the iodotyrosine 
dehalogenase to allow recycling of the iodide. 
THYROID HORMONES IN PERIPHERAL TISSUES 
 A wide variety of iodothyronines and their metabolic 
derivatives exist in plasma. Of these, T4 is highest in 
concentration and the only one that arises solely from direct 
secretion by the thyroid gland. In normal humans, T3 is also 
released from the thyroid, but approximately 80% is derived 
from the peripheral tissues by enzymatic removal of a single 
5' iodine atom from T4 (outer ring or 5' monodeiodination)(19). 
The plasma proteins with which T4 is mainly associated are 
TBG, transthyretin (TTR, formerly termed T4-binding 
prealbumin  [TBPA]), and albumin . About 75% to 80% of T3 
is bound by TBG, and the remainder by TTR and albumin.  
Because TBG is the principal T4- and T3-binding protein, 
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changes in TBG or its binding are paralleled by changes in 
total plasma T4 and T3 even though T4 and T3 production is 
little changed. 
 The TBG binding site has an affnity for T3 that is about 
20-fold less than that for T4. 
The affinity of albumin for T4 and T3 binding is much lower 
than that of either TBG or TTR, but because of its high 
concentration this protein binds 10% of the plasma thyroid 
hormones. Between 3% and 6% of plasma T4 and T3 are 
bound to lipoproteins. In normal serum, the free T4 is 
approximately 0.02% of the total (about 20pmol/L, or 
1.5ng/dL). The approximately 20-fold lower affinity of TBG 
for T3 results in a higher proportion of unbound T3 (0.30%). 
If a change in TBG occurs, the free T4 and T3 concentrations 
can be maintained at normal levels only if the bound hormone 
changes in the same direction. For example, if TBG 
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concentrations are increased by administration of estrogen, the 
reduction in free T4 lessens T4 clearance, allowing allowing 
an increase in the plasma total T4 concentration. This is an 
iterative process that eventually normalizes the free T4 at a 
new equilibrium without a change in T4 secretion rate. 
The most important pathway for T4 metabolism is its outer 
ring (5') mono deiodination to the active thyroid hormone, T3. 
This reaction is catalyzed by D1 and D2 and is the source of 
more than 80% of the circulating T3 in humans. Inner ring 
deiodination, an inactivating step, is catalyzed primarily by 
D3, which inactivates T3 and prevents activation of T4 by 
converting it to rT3 (19,20). 
Tissues expressing D3 have lower T3 concentrations than 
would be expected from the plasma contribution and a gene 
expression profile similar to that of hypothyroid cells. This is 
explained by the inactivation of T3 and T4 that takes place 
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immediately after these hormones enter the cell. The D3-
mediated reduction in T3 levels likely occurs in several 
physiologic settings (e.g., development, regeneration) 
orpathologic conditions (e.g., cancer cells, inflammation, 
myocardial infarction) in which D3 is upregulated(21). 
Reduced production of thyroid hormone is the central feature 
of the clinical state termed hypothyroidism(22,23). Subclinical 
hypothyroidism is defined as an elevated serum TSH level 
with a norma serum fT4 concentration(24). Subclinical 
hypothyroidism can progress to overt hypothyroidism(25), 
which is defined as increased TSH with decreased in FT4. 
Central hypothyroidism is the result of TSH deficiency caused 
by acquired or congenital hypothalamic or pituitary gland 
disorders. TSH deficiency caused by pituitary dysfunction is 
called secondary hypothyroidism, and that of hypothalamic 
origin is called tertiary hypothyroidism; however, this 
distinction is not necessary in the initial separation of primary 
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from central hypothyroidism. Dopamine, dobutamine, high-
dose glucocorticoids, and severe illness may suppress TSH 
release transiently, leading to a pattern of thyroid hormone 
abnormalities suggesting central hypothyroidism(26). 
RELATION BETWEEN THYROID HORMONE AND 
LIVER: 
Liver plays an important role in metabolism of thyroid and 
gonadal hormoneslike conjugation, excretion, peripheral 
deiodination, and synthesis of thyroid-binding globulin (TBG) 
and sex hormone-binding globulin (SHBG)(4-7.) The liver, and 
to a lesser degree the kidneys, play a dominant, although often 
under-discussed role in the metabolism of thyroid hormones. 
The majority of the most metabolically active thyroid 
hormone, 3,5,3'triiodothyronine(T3), is generated in 
peripheral tissue. Similarly, the preponderance of its 
competitive inhibitor, 3,3',5'-triiodothyronine (rT3; reverse 
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T3)  is generated outside the thyroid gland. Further 
transformations to T2 and T1 isomers also occur almost 
exclusively in peripheral tissue. 
A second pathway of thyroid hormone metabolism involves 
the conjugation of the phenolic hydroxyl group of the outer 
phenolic ring with sulfate or glucuronic acid. These 
conjugation reactions occur primarily in the liver, and to a 
lesser degree in the kidney, and result in biotransformation of 
T4 and T3. The resultant metabolites are primed for 
elimination and are considered relatively inactive.(27)Although 
T4, T3, and rT3 are generated within the thyroid gland, T4 is 
quantitatively the major secretory product. All T4 found in 
circulation is generated in the thyroid unless exogenously 
administered. Production of T3 and rT3 within the thyroid is 
relegated to very small quantities and is not considered 
significant compared to peripheral production(27,28,29) . In 
peripheral tissues, T4 is either converted to T3 or rT3, or 
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eliminated by conjugation, deamination, or decarboxylation 
reactions. It is estimated that more than 70 percent of T4 
produced in the thyroid is eventually deiodinated in peripheral 
tissues, either at the outer phenolic ring to form T3 or at the 
inner tyrosyl ring to form rT3. T3 is considered to be the most 
metabolically active thyroid hormone.  
Although some T3 is produced in the thyroid, approximately 
80-85 percent is generated outside the thyroid, primarily by 
conversion of T4 in the liver and kidneys(30,31).  Similar to T4, 
the majority of circulating T3 is in a bound form; however, 
TBPA and albumin (not TBG) are the binding molecules with 
highest affinity for T3. The free form of T3 (fT3) found in 
circulation is more than an order of magnitude greater than 
fT4, with estimates suggesting fT3 is approximately 8-10 
percent of circulating T3(27). 
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 As the liver, and to a lesser extent kidneys, have primary 
influence on the circulating levels of thyroid hormone 
metabolites, the health and function of these organs play a 
critical and under-appreciated role in thyroid hormone 
function(32).Deiodination of T4 to form T3 or rT3 and the 
subsequent disposal of rT3 occurs in the liver and kidneys.  
Available evidencesuggests that, under some circumstances, 
the activity of hepatic antioxidant enzyme systems and lipid 
peroxidation might influence the peripheral metabolism of 
thyroid hormones. Hepatic decarboxylation and deamination 
enzyme reactions are also capable of influencing the 
formation and elimination of specific thyroid hormone 
metabolites. 
Currently, three deiodinase families are recognized and are 
termed isoforms type I, II, and III. These three families differ 
in terms of their tissue distribution, reaction kinetics, 
efficiency of substrate utilization, and sensitivity to 
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inhibitors(33). Type I deiodinase is the major enzyme in the 
liver, kidneys, and skeletal muscle; it can carry out both 5'- 
and 5-deiodination of T4 to produce either T3 or rT3. Type I 
5'-deiodinase is a selenium-dependent enzyme, with 
selenocysteine at the active site of the enzyme; however, type 
I 5deiodinase enzyme does not require selenium for activity. 
Type II enzyme is the major deiodinase in the brain, pituitary, 
and brown adipose tissue.  Since tissue equipped with type II 
isoforms are relatively independent of circulating T3 for their 
metabolic demands, type II 5'-deiodinase is particularly 
important for providing the T3 required to stimulate the 
pituitary to synthesize and secrete TSH. Two Types III 
deiodinase isoform is also found in the central nervous system 
and catalyzes the 5-deiodination of T4, resulting in generation 
of rT3. 
In the course of chronic liver disease such as hepatic cirrhosis, 
alterations in hepatic deiodination resulting in increased rT3 
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and a simultaneous decrease in T3 levels have also been 
observed(34). 
In animal models, ethanol intake was associated with 
impaired hepatic 5'deiodination(35). 
Among patients with alcohol induced liver cirrhosis, low T3 
and T4, elevated rT3, and normal TSH values have been 
observed(36). While extreme alcohol-induced liver damage is 
apparently detrimental to the peripheral modulation of thyroid 
hormones, it is unclear whether moderate alcohol intake has 
an impact. 
Specific forms of chronic liver disease 
In patients with chronic hepatitis associated with primary 
biliary cirrhosis (PBC) or chronic autoimmune hepatitis, there 
is an increased prevalence of autoimmune thyroid 
disease(37,38). Thus abnormalities may arise from thyroid gland 
dysfunction or as a consequence of the liver disease. 
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Autoimmune hypothyroidism is a prominent feature in PBC, 
occurring in 10–25% of patients39. There is often an increase 
in total T4 in PBC, due to an increase in thyroid‐binding 
globulin levels, and this may mask hypothyroidism, 
emphasizing the need to perform a free T4 and TSH assay. 
Anti‐thyroid microsomal antibodies are common in PBC 
(34%), as are anti‐thyroglobulin antibodies (20%)40. Thyroid 
dysfunction may precede or follow the diagnosis of PBC. In 
autoimmune hepatitis, both Grave's disease (6%) and 
autoimmune hypothyroidism (12%) are relatively common38. 
Primary sclerosing cholangitis is associated with an increased 
incidence of Hashimoto's thyroiditis, Graves's disease and 
Riedel's thyroiditis41. 
In patients with chronic hepatitis who do not have co‐existing 
autoimmune liver and thyroid disease, total T4, total T3, 
thyroxine‐binding globulin levels are often increased, but 
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TSH and free T4 levels are usually normal, and patients are 
clinically euthyroid8. 
Currently the treatment of viral hepatitis with alpha interferon 
has added another dimension to the abnormalities of thyroid 
function seen in chronic liver diseases. In different studies 
assessing patients treated with alpha interferon for hepatitis C, 
2.5–10% developed thyroid dysfunction(42,43), with both 
thyrotoxicosis (due to acute thyroiditis) and hypothyoidism 
being observed. Although the reason is not altogether clear, 
the induction of an autoimmune reaction has been postulated, 
resulting in the development of anti‐thyroid and 
anti‐thyrotrophin receptor antibodies44. However, a distinct 
effect on intrathyroidal organification of iodine has also been 
suggested45. It should be noted that interferon therapy causes 
weakness and muscle aching, and in this setting the myopathy 
of hypothyroidism may be missed. It is therefore 
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recommended that thyroid function tests (including thyroid 
antibodies) are performed prior to therapy, and subsequently 
monitored at 3–6 month intervals during interferon therapy46. 
In chronic hepatitis B, predominantly a disease of males, the 
frequency of pre‐treatment thyroid antibodies and the 
induction of thyroid antibodies and thyroid dysfunction during 
interferon therapy, are all lower than in chronic hepatitis C47. 
Overall, the majority of patients with liver disease are 
clinically euthyroid, and this can be confirmed with a normal 
high sensitivity TSH test and a normal free T4. The latter test 
is routinely performed and obviates the need to take into 
account the variation in thyroid‐binding globulin levels seen 
in patients with liver disease. 
Assessment of thyroid and gonadal function in liver diseases 
was conducted on about 75 patients by Sandeep kharb et al(48) 
with acute hepatitis (AH), chronic liver disease (CLD), and 
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those who had undergone liver transplantation (LT). Patients 
with chronic liver disease further subdivided according to 
child pugh score which includes CLD-1(CTP A) and CLD-
2(CTP B and C).Thyroid dysfunction was noted in 14 
patients(16%) of patients with liver disease. Among thyroid 
dysfunction, the commonest was sick euthyroid syndrome six 
(7%), followed by subclinical hypothyroidism in three 
patients (3.5%), subclinical hyperthyroidism and 
thyrotoxicosis in two patients each (2.3%) and overt 
hypothyroidism in one patient. Among patients with LT and 
AH groups, the only abnormality was significantly lower total 
T3 compared with healthy controls. The CLD2 group had 
significantly lower levels of all thyroid hormones compared 
with controls and CLD1 group. 
Indian study conducted by G.Deepika et a,(49) on about 310 
cirrhotic patients aged 20-80years, to find out Prevalence of 
hypothyroidism in Liver Cirrhosis among Indian patients. 
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Both genders were included .Male are 211 and Female are 99. 
The control group comprised randomly selected non cirrhosis 
subjects. The total number of control subjects is 250 aged 20-
80 years. Male are 145 and female are 105. The result showed 
that there was a significantly increased between cirrhotic 
patients and non-cirrhotic subjects for TSH and slightly 
decreased T3 andT4 where the p value is 0.039, 0.014 and 
0.245 respectively. The mean of TSH levels of cirrhotic 
patients is higher than the mean of non-cirrhotic subjects and 
show significant difference. And also there is significant 
difference for T3 between two groups, but T4 seems no 
significant difference between two groups. 
A study conducted by K.V.S.Harikumar et al(50) on occult 
endocrine dysfunction in patients with cirrhosis of liver 
consists of 30 patients which shows that 30% of patients were 
found to be thyroid dysfunction. That include subclinical 
hypothyroidism (n = 3), primary hypothyroidism (n = 1), Sick 
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Euthyroid syndrome (n = 3), central hypothyroidism (n = 2) 
and secondary hypogonadism (n = 3). But none of the results 
was statistically significant individually. But considering 
hypothyroidism as a single entity which includes all subtypes, 
it was found out to be statistically significant.  
Serum Level of Thyroid Hormones in Patients with Chronic 
Hepatitis C Virus Infection by Mohamed Abdel-Fattah El-
Feki et al(51) on about 60 patients with CHC infection were 
selected for the study. They were divided into two groups: 
with or without liver cirrhosis. Those with liver cirrhosis were 
further subdivided according to the Child-Turcotte-Pugh 
scoring system. Serum levels of free T3 (FT3), free T4 (FT4) 
and TSH were measured to all patients. Results shown that 
there was decrease in the FT3 and FT4 levels and increase in 
the TSH levels in patients with CHC with cirrhosis when 
compared to patients with CHC without cirrhosis. This study 
concludes that thyroid profile abnormalities were seen in 
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cirrhotic HCV patients when compared to non-cirrhotic 
patients. The abnormalities in the serum level of THs 
(decreased FT3, FT4, and increased TSH) are strongly 
associated with the severity of liver damage and advancing of 
the child score. 
Oren R et al(52) conducted a reterospective study on 
hypothyroid versus the euthyroid state, a significant negative 
correlation was found between thyroid-stimulating hormone 
blood levels and both functional and synthetic liver function 
tests (p < 0.001). A significant negative correlation was also 
found between thyroid-stimulating hormone blood levels and 
clinical deterioration manifested as bleeding varices, the 
development of ascites, and episodes of encephalopathy. We 
conclude that in patients with liver cirrhosis, the liver function 
in the hypothyroid state tend to be better than in the euthyroid 
state. A mild controlled decreased thyroid function may be 
beneficial for euthyroid cirrhotic patients. 
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Takahashi1 et al(53) conducted a study on changes of thyroid 
hormones in various liver diseases: usefulness of free thyroid 
hormones as liver function test. Various thyroid parameters in 
liver disease which were morphologically diagnosed were 
measured, and their relationship to liver function was mainly 
studied. Serum T4 levels were elevated in acute hepatitis 
(AH), chronic persistent hepatitis (CPH) and chronic 
aggressive hepatitis (CAH)compared with in normal controls 
(C). Serum T3 levels were elevated in CAH and reduced in 
liver cirrhosis (LC). Serum reverse T3 (rT3) levels were 
elevated in AH and chronic liver diseases (CLD). T3/T4 ratios 
decreased in AH, CPH and CAH. RT3/T3 ratios increased in 
AH and CLD. Serum Free T3 (FT3) levels reduced in CLD in 
order of CPH, CAH and LC, and were low levels in AH with 
the same degree as LC. Moreover, serum FT3 levels positive 
correlation with prothrombin time (PT) and serum albumin 
levels (Alb). Therefore serum FT3 level was considered to 
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become a sensitive index of liver damage. Serum free T4 
(FT4) levels did not change significantly in AH with high 
levels of transaminases and reduced in only LC. Therefore 
serum FT4 may become an index of severity of liver 
dysfunction. On the other hand, T3/T4 ratios and rT3/T3 
ratios showed less correlation with liver function tests 
compared with free thyroid hormones. 
M Borzio et al(8) evaluate thyroid function in patients with 
liver disease, they measured total and free T3 and T4, 
thyroxine binding globulin, basal and thyrotropin releasing 
hormone-stimulated thyrotropin and thyroglobulin antibodies 
in 33 patients with liver cirrhosis, T3, FT3 and T3/thyroxine 
binding globulin and thyrotropin after thyrotropin releasing 
hormone were significantly reduced. 
The study conducted on Serum Thyroid Hormone Levels in 
Sudanese Patients with Liver Cirrhosis by Hussein Awad 
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Mousa et al(54) The study revealed significant decrease level of 
T3 (p value <0.05) in cirrhotic patients than controls, while 
TSH and T4 were    insignificantly changed. It also appears 
that there was no significant correlation between duration of 
cirrhosis and thyroid hormones among cirrhotic patients.  
Fariborz Mansour-Ghanaei et al(55) conducted a study on  
Thyroid hormones profile in patients with hepatic cirrhosis 
due to chronic HBV and HCV infections was evaluated in 
order to find any relationship between thyroid hormones and 
severity of liver damage. Patients with the diagnosis of 
hepatic cirrhosis due to hepatitis B or C were screened for 
thyroid function status. Child-Pugh and model for end-stage 
liver disease (MELD) scores were calculated. Considering 
each thyroid function test, patients were divided into two 
groups with lower than normal and normal range of thyroid 
hormones, separately for each (for TSH, normal and upper 
than normal). The correlation between thyroid function tests 
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and severity of liver disease was taken into account.  Number 
of patients with a T3 level lower than normal range (70-110 
ng/dL) significantly increased along with Child-Pugh scores 
A, B and C. A negative correlation was found between Child-
Pugh scores and total serum T3 level (r = -0.453, P < 0.001). 
Also a reverse correlation was observed between MELD score 
and T3 levels (r = -0.305, P = 0.14). Study concluded that 
serum T3 concentration is a good index of hepatic function, 
decreasing by the severity of liver damage. 
Sanul A et al(56), studied conducted a study on 55 patients with 
liver cirrhosis and compared with 78 controls concluded that 
The mean serum concentration of T3, FT3 and FT4 were 
significantly decreased in cirrhotics, while no significant 
change was noted in serum T4 and TSH levels. T3/T4 ratio 
was also lower than the normal. This indicates an impaired 
liver conversion of T4 to T3 in peripheral tissues. Serum T3 
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and FT3 showed an inverse correlation with serum bilirubin 
and a positive correlation with serum albumin. 
Summary and perspectives: 
The liver is a major site of peripheral conversion, degradation 
and excretion of thyroid hormones. Therefore, abnormal 
thyroid function at all levels of hypothalamic-pitutary-thyroid 
axis is expected in patients with liver cirrhosis(57). 
Several abnormal alterations in the thyroid gland have been 
identified in patients with cirrhosis, these ranges from 
alterations in thyroid size, morphology and architectural 
pattern to alteration in thyroid hormone metabolism and 
regulation. 
The volume of the thyroid gland is reported to increase by 
upto 17% in cirrhosis patients compared with non-cirrhotic 
controls, as measured using ultrasonography(58). The 
prevalence of thyroid hormone abnormality ranged from 13% 
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to 61%. In patients with cirrhosis, hypothyroidism was more 
frequently seen, and hyperthyroidism has also been 
reported(59).  The most consistent thyroid hormone profile in 
patient with cirrhosis is low total and free T3 and elevated rT3 
levels, similar to changes in patients with sick euthyroid 
syndrome. This results in a decrease in conversion of T4 to 
T3. The T3:Rt3 ratio parameter of liver function(60,61,62-66). 
Regarding the association between severity of cirrhosis and 
thyroid function, low T4 levels may be related with decreased 
short and long term survival of patient with liver cirrhosis(61). 
Low T3 levels are a good indicator of disease severity in 
cirrhosis(67).A negative correlation was found between child-
pugh scores and total serum T3 levels(55). 
Low total and free T3 levels may be considered an adaptive 
condition that contribute toreducing the basal metabolic rate 
within hepatocytes to preserve liver function. Indeed, recent 
52 
study showed a significant improvement of liver function, 
including alanine aminotransferase, alkaline phosphate, 
albumin, bilirubin and prothrombin time in patients with 
increased TSH. 
Also in case of stable cirrhosis, a hypothyroidism has been 
shown which correlates with slow progression of stage of 
cirrhosis(68,52). Therefore thyroid dysfunction may disturb liver 
functions and liver diseases modulate thyroid hormones 
metabolism(5).However further studies are required to test this 
hypothesis. As thyroid hormone disorders are prevalent in 
liver cirrhosis, awareness of thyroid function in liver disease 
is necessary.           
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AIMS AND OBJECTIVES 
1. To study the occurrence of hypothyroidism in patients 
with chronic liver disease. 
2. To study the relationship between serum FT3 and child-
pugh score. 
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MATERIALS AND METHODS 
INCLUSION CRITERIA: 
-Patients with age >18years, either sex with evidence of 
chronic liver disease. 
EXCLUSION CRITERIA: 
1. -known case of hypothyroidism on treatment 
2. -Pregnant female 
3. -Medications that affect study like phenytoin, 
amiodarone, NSAIDS, Salicylates. 
4. - Patients with sepsis 
STUDY DESIGN: Cross sectional observational study 
STUDY PERIOD: september 2016 to september 2017 
STUDY PLACE: Dept. of Medicine, kanyakumari 
government medical college. 
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SAMPLE SIZE: Minimum 50 cases 
CONTROL: 50 age, sex matched controls from hospital 
health care group personnel. 
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METHODOLOGY 
*Patients of chronic liver are selected for our study on the 
basis of: 
*Duration of disease greater than 6 months    
In practical clinical terms diagnosis of chronic liver disease is 
made in the presence of duration >6 months(11). Cirrhosis, a 
final pathway for a wide variety of chronic liver diseases, a 
combination of clinical(signs and symptoms of liver cell 
failure), laboratory (raised bilirubin, SGOT, SGPT, low 
albumin), and imaging features (absence of thin hyper echoic 
line, paucity of peripheral hepatic vessels, accentuated 
echogenic walls of the portal vein, nodular liver cirrhosis, 
contracted, signs of portal hypertension)  can help to confirm 
the diagnosis(12).   
* Child pugh score >6. Child pugh score was calculated 
according to the table 
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As most of the in and out patients presents to our hospital in 
later stages of disease so cases belongs to CTP B and C are 
included in the study and compared. 
     MEASURE 1 POINT       2 POINTS      3 POINTS 
Total bilirubin 
µmol/l(mg/dl) 
<34(<2) 34-50(2-3) >50(>3) 
Serum albumin, g/dl >3.5 2.8-3.5 <2.8 
PT INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to severe 
Hepatic 
encephalopathy 
None Grade 1-2 Grade 3-4 
 
 *USG findings suggestive of chronic liver disease like- 
 Nodular irregular surface of liver 
 Distorted vascular pattern 
 Ascites 
 Signs of portal hypertension (splenomegaly or dilated 
portal venous system on ultrasonography) 
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* Evidence of esophageal varices on upper gastro intestinal 
endoscopy. 
1. All patients will undergo a detailed clinical examination 
at admission. Relevant history and physical examination 
including symptom and signs of liver failure, 
hepatomegaly, splenomegaly and abdominal vein 
collaterals will be recorded. Ascites will be graded as 
none, mild, moderate and severe. 
2. Haematological and biochemical workup will include 
measurement of    haemoglobin, total leucocyte count, 
platelet count, prothrombin time and serum concentration 
of bilirubin (both direct and indirect), protein , albumin, 
alanine aminotransferase and aspartate aminotransferase. 
For each patient a child pugh score will be calculated (69). 
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3.Ultrasonography 
All patients will undergo ultrasonography after overnight 
fast and the following details will be recorded: Maximum 
vertical span of liver; nodularity of liver surface; spleen 
size (length of its axis); diameter of portal and splenic 
veins ;presence of portal-systemic collaterals; and 
presence of ascites. 
4.Hormonal assessment 
 Blood tests are currently the most accurate way to 
diagnose thyroid disorders. Fasting venous sample taken 
in the vaccutainer in the early morning is the best method 
to test thyroid hormones level(70).                                             
FT3 and FT4 - Free T3 and FT4 tests will be performed 
using the VITROS free T3 and free T4 reagent pack and the 
VITROS free T3 and free T4 calibrators on the VITROS 
ECi/ECiQ Immunodiagnostic system. 
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TSH 
TSH levels are determined by VITROS TSH test. VITROS 
TSH test is performed using the VITROS TSH Reagent and 
system using Intellicheck technology. An immediate 
immunoassay technique is used, which involves the 
simultaneous reaction of TSH present in the sample. 
The normal values of the thyroid function test were taken as 
the following according to the bio-chemistry laboratory. 
Kanyakumari government  medical college , where the 
evaluation was carried out.  
TSH---- 0.5-5.0IU/ml  
FT3-----2.0-4.4pg/dl 
FT4----0.6-2.2ng/dl 
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STATISTICAL ANALYSIS 
Categorical variables were presented in number and 
percentage (%) and continuous variables were presented as 
mean ± SD and median. Normality of data was tested by 
Kolmogorov-Smirnov test. If the normality was rejected then 
non parametric test was used.  
Statistical tests were applied as follows- 
1.Quantitative variables were compared using Unpaired t-
test/Mann-Whitney Test (when the data sets were not 
normally distributed) between the two groups. 
2.Qualitative variables were correlated using Chi-Square test 
/Fisher’s exact test. 
3. Spearman rank correlation coefficient was used to assess 
the association of CTP score with various parameters. 
A P value of <0.05 was considered statistically significant. 
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The data was entered in MS EXCEL spreadsheet and analysis 
was done using Statistical Package for Social Sciences (SPSS) 
version 21.0. 
OBSERVATION AND RESULTS 
A total of 50 patients with chronic liver disease were enrolled 
in the study and 50 age and sex matched healthy controls were 
controlled. 
1.Patient characteristics 
Table 1-Age Distribution Among studyGroups- 
         Case Control 
 Mean±Stdev Mean±Stdev 
         44.38±9.33 41.84±8.24 
 
 Thus, cases showed a mean age of 44.38±9.33 and controls a 
mean age of 41.84±8.24. There was no significant difference 
between age of cases and controls. 
 
Table 2-Age grouping 
            Group   Total P value  
 Case Control  
Age 
distribution 
1)<=30 6(12.00%) 6(12%) 12(12%) 0.299  
2)31-40 10(20%) 15(30%) 25(25%)  
3)41-50 21(42%) 23(46%) 44(44%)  
4)>50 12(26%) 6(12%) 6(6%)  
  50(100%) 50(100%) 100(100%)  
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Figure 2-Age grouping 
 
 
Table 3-Sex Distribution Among study group- 
               Group  
Total 
 
P value Case Control 
Sex Female 11(22%) 14(28%) 25(25%)  
0.488 Male 39(78%) 36(72%) 75(75%) 
Total  50(100%) 50(100%) 100(100%) 
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Figure 3-Sex Distribution Among study group2% 
 
Thus, out of 50 cases 39(78%) are males and 11(22%) are 
females. Out of 50 persons in control group 36(72%) males 
and 14(28%) are females. 
 
 
Table 4- Hypothyroidism distribution 
            Group  
Total 
 
P value    Case   Control 
Occurance of 
hypothyroidism 
       No 44(88%) 50(100%) 94(%)  
0.027       Yes 6(12%) 0(0.00%) 6(6%) 
Total  50(100%) 50(100%) 100(100%) 
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Figure 4-hypothyroidism distribution 
 
Thus this study shows hypothyroidism is present in 6(12%) 
patients with chronic liver disease with a statically significant 
p value of 0.027. 
Table 5- Distribution of Hypothyroidism in different 
child-pugh score 
                        CTP  
     Total             B          C 
Occurrence of 
hypothyroidism 
          No       92.86%        81.82%      88% 
        Yes        7.14%         18.18%       12% 
    Total          100%         100%       100% 
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Figure 5-Distribution of Hypothyroidism in different 
Child-pugh score
 
Out of 28 patients belongs to child-pugh score B 2(7.14%) 
patients are found out to be Hypothyroidism. 4(18.8%) out of 
22 patients in child-pugh C are found to be hypothyroidism. 
Table –6: Subclinical hypothyroidism among study group 
             Group  
  Total 
 
P value     Case  Control 
Subclinical 
hypothyroidism 
      No     48(96%)    50(100%)  98(98%)  
0.495        Yes      2(4%)     0(0.00%)   2(2%) 
               Total 50(50%) 50(100%) 100(100%) 
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Figure-6: subclinical hypothyroidism among study group 
 
Thus this study shows that out of 50 cases subclinical 
hypothyroidism is present in 2(4%) patients with chronic liver 
disease with statistically insignificant P value of 0.495. 
Table 7-Overt hypothyroidism in study group 
               Group  
Total 
 
P value   Case Control 
Overt 
hypothyroidism 
      No 49(98%) 50(100%) 99(99%)  
1.000        Yes     1(2%) 0(0.00%) 1(1%) 
  50(100%) 50(100%) 100(100%) 
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Figure 7-Overt hypothyroidism in study group 
 
This study shows that out of 50 cases, overt hypothyroidism is 
present in 1(2%) patient with chronic liver disease with 
statistically insignificant P value of 1.00 
 
Table 8-central hypothyroidism among study groups 
           Group  
  Total 
 
P value   Case    Control 
Central 
hypothyroidism 
   No 47(94%) 50(100%) 97(97%)  
0.242      Yes     6(6%) 0(0.00%) 3(3%) 
          Total 50(100%) 50(100%) 100(100%) 
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Table-8-central hypothyroidism among study groups 
 
 
Central hypothyroidism is present in 3(6%) out of 50 patients 
in our study with insignificant p value of 0.242 
 
Table 9-subclincal hypothyroidism with CTP 
                           CTP  
      Total          B             C 
Subclinical 
hypothyroidism 
        No       96.43%         95.45%        96.00% 
          Yes          3.57%          4.55%           4% 
                   Total         100%           100%          100% 
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Figure 9-subclinical hypothyroidism with CTP 
 
1(3.57%) out of 28 patients in Child-pugh B and 1(4.55%) out 
of 22 patients with CTP C are found to be subclinical 
hypothyroidism 
Table 10-overt hypothyroidism with CTP 
                 CTP  
        Total         B           C 
         Overt 
hypothyroidism 
          No        100%       95.45%              98% 
        Yes        0.00%        4.55%              2% 
                       Total           100%        100%             100% 
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Figure 10-overt hypothyroidsm with CTP 
 
 
1(4.55%) out of 22 patients with CTP C is overt 
hypothyroidism but none in CTP B is belongs to this category. 
 
 
Table – 11 Central hypothyroidism with CTP score 
                     CTP  
      Total           B           C 
Secondary 
hypotjyroidism 
        No        96.43%          90.91%        94.00% 
          Yes        3.57%            9.09%           6.00% 
                  Total           100%           100%             100% 
100%
0%
95.45%
4.55%
0%
20%
40%
60%
80%
100%
120%
No Yes
OVERT
%
 O
F 
TO
TA
L N
O
 O
F 
PA
TI
EN
TS
OVERT * CTP
B C
Figure -11 central hypothyroidism with CTP score 
 
1(3.57%) out of 28 in CTP B and 2(9.09%) out of 22 patients 
in CTP C are found to be secondary hypothyroidism  
 
Table 12-Bilrubin among study group 
Bilrubin                Case         Control     P value 
     Sample size               50            50  
<0.001 Mean±Stdev         2.61±1.12          0.64±0.22 
         Median            2.3              0.6 
        Min-Max         0.6-6.9          0.2-1.1 
Interquartile range   1.900-3.100     0.500-0.800 
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Table 12-Bilrubin among study group 
 
Thus, bilrubin is significantly higher in case group with a 
mean 2.3mg/dl as compared to control group with a mean of 
0.6mg/dl.Pvalue is <0.001 
Table 13-FT3 among study groups 
         Case       Control     P value 
       Sample size             50        50  
     0.001 Mean±Stdev         2.44±0.72 2.81±0.52 
     Median           2.27      2.84 
   Min-Max        1.41-4.2      1.78-4 
Interquartile 
range 
   1.910-2.810 2.450-3.100 
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 Figure 13-FT3 among study groups 
 
 
Thus, FT3 is significantly lower in case groups with a mean of 
2.44 as compared to control group with a mean of 2.81and it s 
found to be statistically significant with P value of 0.001 
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Table 14-FT4 among study groups 
        Case        Control     P value 
Sample size          50          50  
    0.285 Mean ± St dev      1.43±0.61      1.29±0.42 
  Median           1.34         1.1 
   Min-Max    0.41-3.04    0.74-2.17 
Interquartile range      0.960-1.860    1.020=1.550 
 
 
Figure 14-FT4 among study group 
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Thus,FT4 is higher in case group with a mean of 1.43 
compared to control with a mean of  1.29 and it is statistically 
insignificant. 
Table -15 TSH among study groups 
               Case            Control      P value 
       Sample size             50                 50  
0.008      Mean ± St dev          2.55±2.57        2.86±0.89 
         Median            2.09                2.94 
      Min-Max    0.13-14.7    1.38-4.48 
Interquartile range    0.780-3.200    2.060-3.470 
 
Figure 15- TSH distribution among study groups 
 
2.55
2.86
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
Case Control
M
EA
N
 V
A
LU
ES
TSH
Thus,TSH is significantly lower in case group with a mean of 
2.55 as compared to control group with a mean of 2.86 and it 
is found to be statistically significant. 
Table 16-FT3 distribution among study groups 
           Group  
 Total 
 
P value       Case    Control 
FT3 
distribution 
Decreased  14(28%)   1(2%) 15(15%)  
0.0004 Normal 36(72%) 49(98%) 85(85%) 
               Total 50(100%)  50(100%) 100(100%) 
 
 
Figure 16-FT3 distribution among study groups 
 
28%
72%
2%
98%
0%
20%
40%
60%
80%
100%
120%
Decreased Normal
FT3 distribution
%
 O
F 
TO
TA
L 
N
O
 O
F 
PA
TI
EN
TS
FT3 distribution * Group
Case Contol
FT3 is found to be decreased in 14(28%) patients out of 50. 
1(2%) out of 50 controls found to be low FT3. P value is 
found to be 0.0004 
Table 17-FT3 distribution with child pugh score 
                  CTP  
   Total 
 
  P value         B         C 
   FT3 
distribution 
 Decreased   4(14.29%)   10(45.45%)    14(28%)  
0.025 Normal    24(85.71%)     
12(54.55%) 
  36(72%) 
              Total    28(100%)     22(100%)     50(100%) 
 
 
Figure 17-FT3 distribution with child pugh score 
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Among 28 patients in child pugh B FT4 is found to be 
decreased in 4(14.29%) patients. Out of 22 patients in child 
pugh C FT3 is found to be decreased in 10(45.45%) patients. 
 
 
Table 18-FT4 distribution among study groups 
        Group  
   Total 
 
P value   Case  Control 
FT4 
distribution 
Decreased    4(8%) 0(0.00%)  4(4.00%)  
 
0.013 
 Increased     4(8%) 0(0.00%) 4(4.00%) 
   Normal      
42(84%) 
50(100%) 92(92%) 
                Total      
50(100%) 
50(100%) 100(100%) 
 
 
 
 
Figure 18-FT4 distribution among study groups 
 
Out of 50 cases 4(8%) patients are found to be increased and 
4(8%) patients are found to be decreased FT4. None of the 
controls shows any variation. P value is found to be 
statistically significant of 0.013 
Table 19: TSH distribution among study groups 
                Group  
 
  Total 
 
 
P value       Case    Control 
TSH 
distribution 
Decreased     4(8%)   0(0.00%)    4(4%)  
 
 
0.023 
Increased     3(6%)    0(0.00%)    3(3%) 
Normal   43(86%) 50(100%) 93(93%) 
                   Total  50(100%) 50(100%) 100(100%) 
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 Figure 19:TSH distribution among study groups 
 
 
 
TSH levels found to be decreased in 4(8%) and increased in 
3(6%) out of 50 cases. None of the controls shows any 
variation. P value is found to be stastistically significant. 
 
Table 19:Correlation between TSH and child-pugh 
score 
 
 
 
               TSH 
Correlation co-efficient             -0.176 
               P value               0.2224 
           Sample size                 50 
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 Figure 19:Correlation between TSH and Child-pugh score 
 
 
TSH is found to be negatively correlated with Child-pugh 
score with correlation co-efficient of -0.176 but it is found to 
be statistically insignificant with P value of 0.2224 
 
 
Table 20: Correlation between FT4 and Child-pugh score 
 
 
 
            FT4 
Correlation co-efficient              -0.191 
       P value             0.1849 
       Sample size                 50 
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Figure 20: Correlation between FT4 and Child-pugh score 
 
 
FT4 is found to be negatively correlated with Child-pugh 
score with correlation co-efficient of -0.191 which is 
statistically insignificant P value of 0.1849 
 
 
 
Correlation between FT3 and Child-pugh score: 
 
                    FT3 
Correlation Coefficient               -0.57 
 Significance Level P <0.001 
      Sample size               50 
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Correlation between FT3 and Child-pugh score: 
 
FT3 is found to be negatively correlated with Child-pugh 
score with correlation co-efficient of -0.57 and P value of 
0.001 
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DISCUSSION 
In our study 50 patients with chronic liver disease were 
enrolled and they underwent a detailed history, clinical 
examination, hematological and biochemical investigations, 
ultrasonography with portal venous Doppler, upper gastro 
intestinal endoscopy and hormonal evaluation. 50 age and sex 
matched controls were enrolled. Hypothyroidism was studied 
in relation to chronic liver disease and correlation of free 
triiodothyronine with Child-pugh score. 
In practical clinical terms diagnosis of chronic liver disease is 
made in the presence of duration >6 months, indicative 
clinical features, with serum and imaging results. Therefore, 
the utilization ofclinical (signs and symptoms of liver cell 
failure), bio-chemical (raised bilrubin, SGOT, SGPT,low 
albumin),hematological(low hemoglobin, platelets and 
leucocyte count) and radiological(absence of thin hyper 
echoic line, paucity of peripheral hepatic vessels, accentuated 
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echogenic walls of the portal vein, nodular liver cirrhosis, 
contracted, signs of portal hypertension) tools is vital in 
diagnosis of chronic liver disease. 
Patient characteristics: 
50 patients with chronic liver disease were enrolled in this 
study with a mean age of 44.38±9.33 years(range 24-62 
years). 78%(39 patients) were males and 22%(11 patients) 
were females. Similarly 50 controls were enrolled with a 
mean age of presentation 41.84±8.24. 72%(36 controls) were 
male and 28%(14 controls) were females. 
Analysis: 
This study revealed, firstly, that there is a significant 
occurrence of hypothyroidism in chronic liver disease 
patients. Secondly, there is a negative correlation of free 
triiodothyronine with Child-pugh score. 
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In this study, 12% patients (6 patients) with CLD have 
hypothyroidism. Out of which 4%(2 patients) are subclinical 
hypothyroidism, 2%(1 patient) is overt hypothyroidism and 
6%(3 people) are secondary hypothyroidism. Various authors 
have reported that prevalence of thyroid hormone abnormality 
ranged from 13% to 61%. In patients with cirrhosis, 
hypothyroidism was more frequently seen, and 
hyperthyroidism has also been reported(59). This is due to 
varied etiology and severity.  In a study by Sandeep kharb et 
al(48) 4(5.33%) patients out of 75 patients of liver disease 
found to be hypothyroid, in which 3(3.5%) were subclinical 
and 1(1.3%) patient is overt hypothyroid. Out of 30 patients of 
liver cirrhosis in a study conducted by K.V.S.Harikumar et 
al(50) shows subclinical hypothyroidism is present in 10%(3 
patients), central hypothyroidism in 6.66%(2 patients) and 
primary hypothyroidism in 3.3%(1patient). According to 
G.Deepika(49) et al in a study on 310 cirrhotic patients  
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revealed that cirrhotic patients weremore prevalence thyroid 
dysfunction specially hypothyroidismbecause of many 
reasons. This study also shows none of the results was 
statistically significant individually. But considering 
hypothyroidism as a single entity which includes all subtypes, 
it was found out to be statistically significant.  
This study shows that statistically significant decrease in 
Mean FT3 and TSH compare to control with P value of 0.001 
and 0.008 respectively. However our study shows statistically 
insignificant increase in FT4 level. These findings does not go 
with the study conducted by G.Deepika et al(49) showed that 
there was a significantly increased between cirrhotic patients 
and non-cirrhotic subjects for TSH and slightly decreased T3 
and T4 where the p value is 0.039, 0.014 and 0.245 
respectively. These findings are not in agreement with 
Mohamed Abdel-Fattah El-Feki et al(51)   who found that in 
chronic hepatitis C concluded that decrease in the FT3 and 
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FT4 levels and increase in the TSH levels in patients with 
CHC with cirrhosis when  compared to patients with CHC 
without cirrhosis. This is in agreement with Hussein 
AwadMousa(54) who found that a significant decrease level of 
T3 and an insignificant change in TSH and T 4levels than 
control groups. Takahashi et al(53) concluded that serum Free 
T3 (FT3) levels reduced in CLD in order of CPH, CAH and 
LC, and were low levels in AH with the same degree as LC. 
Liver disease is also associated with increase in inflammatory 
cytokines that negatively affect hypothalamo thyroid 
axis,(71,72) which may explain lower TSHlevels (statistically 
not significant) observed in patients with liver disease as 
compared to controls. This may be the hypothesis for central 
hypothyroidism in our study.  Ilias, I., et al., (73)found that in 
cases of prolonged illness, hypothalamic- pituitary 
suppression usually occurred. This leads to decreased 
secretion of TSH, decreased T4 production by the thyroid 
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gland.  Several lines of evidence suggest a reduced dopa-
minergic tone as a consequence of the accumulation of false 
neurotransmitters, which might be responsible for raised basal 
TSH concentrations, as dopamine has been shown to exert an 
inhibitory effect in the regulation of TSH secretion(74). 
Antonelli, A., et al(74)disagreed with our study who found that 
the level of TSH was significantly higher in patients with 
CHC. Increase in total T4 has been observed in patients with 
acute and CLD due to increase in TBG levels, which is 
synthesized as acute phase reactant(10). It can be stated that in 
the initial state of acute liver diseases the total T4 production 
increases and subsequently as liver function is worsen it will 
reduced due the higher and low concentration of TBG, 
respectively. 
Our study  FT3 is significantly lower in case groups with a 
mean of 2.44 as compared to control group with a mean of 
2.81with P value of <0.001.FT3 is found tobe decreased in 
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14(28%) patients out of 50. 1(2%) out of 50 controls found to 
be low FT3. P value is found to be 0.0004. Among 28 patients 
in child pugh B FT4 is found to be decreased in 4(14.29%) 
patients. Out of 22 patients in child pugh C FT3 is found to be 
decreased in 10(45.45%) patients. The correlation co-efficient 
of FT3 with CTP is found to be -0.57 with P <0.001, found 
that FT3 is negatively correlated with CTP. 
This is in agreement withFariborz Mansour-Ghanaei et al(55) 
reported that a negative correlation was found between Child-
Pugh scores and total serum T3 level (r = -0.453, P < 0.001). 
Also a reverse correlation was observed between MELD score 
and T3 levels (r = -0.305, P = 0.14) and concluded that 
concluded that serum T3 concentration is a good index of 
hepatic function, decreasing by the severity of liver damage. 
HusseinAwadMousa et al,.(54) concluded that signi cant 
decrease level of T3 (p value <0.05) in cirrhotic patients than 
controls.This goes with M Borzio et al(8) who evaluated 
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thyroid function in 33 patients with liver disease and found 
that T3, FT3 and T3/thyroxine binding globulin and 
thyrotropin after thyrotropin releasing hormone were 
significantly reduced. According to kahashi H et al(53)  
conducted a study on thyroid hormones in different categories 
of liver disease like acute hepatitis, chronic persistent hepatitis 
and chronic aggressive hepatitis concluded that Serum Free 
T3 (FT3) levels reduced in CLD in order of CPH, CAH and 
LC, and were low levels in AH with the same degree as LC. 
This is in agreement with Sandeepkharb et al(48) who studied 
thyroid function in over 75 patients with AH, CLD and LT 
group concluded that Among patients with LT and AH 
groups, the only abnormality was significantly lower total T3 
compared with healthy controls. This result goes with Sanu A 
at al(56)  who found that serum T3 and FT3 showed an inverse 
correlation with serum bilirubin and positive correlation with 
serum albumin. 
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One more observation in our study shows TSH is found to be 
negatively correlated with Child-pugh score with correlation 
co-efficient of -0.176 but it is found to be statistically 
insignificant with P value of 0.2224. this is agreement with 
Oren R et al(52)  who found a significant negative correlation 
was found between thyroid-stimulating hormone blood levels 
and both functional and synthetic liver function tests (p < 
0.001). 
In this study revealed that decreased total T3 probably reflects 
a decrease in deinodinase1 activity in the liver of cirrhotic 
patients(75,76,64). Several studies concluded that the most 
consistent thyroid hormone profile in patient with cirrhosis is 
low total and free T3 and elevated rT3 levels, similar to 
changes in patients with sick euthyroid syndrome. This results 
in a decrease in conversion of T4 to T3. The T3:Rt3 ratio 
parameter of liver function(60,61,62-66). 
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 Although some T3 is produced in the thyroid, approximately 
80-85 percent is generated outside the thyroid, primarily by 
conversion of T4 in the liver and kidneys.(30,31) 
LIMITATIONS OF THE STUDY: 
 As this was a cross sectional study we could not access 
factors which could have predicted mortality and 
morbidity. 
 Our study data derived from a small group of patients 
do not give enough evidence to suggest that the 
observed endocrinopathies are merely coincidental or 
due to the underlying cirrhosis. Further large scale 
studies with more number of patients are required to 
confirm the findings observed in our study. 
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CONCLUSION AND RECOMMENDATIONS 
This study revealed, firstly, that there is a significant 
occurrence of hypothyroidism in chronic liver disease 
patients. Secondly, there is a negative correlation of free 
triiodothyronine with Child-pugh score.. The present study 
revealed that cirrhotic patients had more prevalent thyroid 
dysfunction specially hypothyroidism because of many 
reasons. 
The liver has important role in thyroid hormone metabolism 
because it is themanufacturer of protein that bind thyroid 
hormone, such as thyroid-binding globulin (TBG), pre-
albumin and albumin. It is also the major site of thyroid 
hormone peripheral metabolism and is involved in its 
conjugation, biliary excretion, oxidative deamination and the 
extra thyroidal deiodination of thyroxin (T4) to triiothyronine 
(T3) and to reverse T3. On the other hand the level of thyroid 
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hormone is also important to normal hepatic function and 
bilirubin metabolism(77,78). 
Conceivably, the disorders of these two organs would interact 
or influence each other. As liver abnormalities worsen the T3 
production from T4 is also reduced. It is believed this 
reduction of T3 which mainly correspond to even lower basic 
metabolism rate, economically can be useful due to preventing 
extra energy waste and keep it for the onset of liver disease or 
any other related syndrome which consume further energy. 
Free T3 concentration corresponding with the state of liver 
disease and it seems the serum T3 concentration directly 
related to liver abnormalities progress. The low total and FT3 
levels may be regarded as an adaptive hypothyroid state that 
serves to reduce the basal BMR within hepatocytes and 
preserve liver function and total body protein stores. It has 
been suggested that low FT3 may confer a survival advantage, 
which adapts an organism to chronic illness by reducing the 
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basal metabolic rate within cells and thereby reducing caloric 
requirements. Oren R, Sikuler et al(68)concluded that 
hypothyroidism has also been associated with lesser degrees 
of decompensation in cirrhosis.(38) Controlled induction of 
hypothyroidism might therefore be beneficial in cirrhotic 
patients, but further studies are required to test this 
hypothesis. Also in stable cirrhosis, a state of hypothyroidism 
has been shown which correlates with slow progression of 
stage of cirrhosis(52,68).Few studies have reported that the low 
thyroid hormones are independent predictors of mortality in 
patients admitted to intensive care units (ICU), suggesting the 
inclusion of the thyroid profile in these scoring systems(79-81). 
In conclusion, thyroid dysfunction forms important part of 
spectrum of Chronic liver disease. Deterioation of functions 
of liver disease predicts presence of thyroid dysfunction and 
these patients should be evaluated for thyroid dysfunction 
periodically. 
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